A Translational In Vivo and In Vitro Metabolomic Study Reveals Altered Metabolic Pathways in Red Blood Cells of Type 2 Diabetes
Por:
M. PALOMINO-SCHATZLEIN, R. LAMAS-DOMINGO, A. CIUDIN, P. GUTIERREZ-CARCEDO, R. MARES, C. APARICIO-GOMEZ, C. HERNANDEZ, R. SIMO and J. HERANCE
Publicada:
1 jun 2020
Resumen:
Clinical parameters used in type 2 diabetes mellitus (T2D) diagnosis and monitoring such as glycosylated haemoglobin (HbA1c) are often unable to capture important information related to diabetic control and chronic complications. In order to search for additional biomarkers, we performed a pilot study comparing T2D patients with healthy controls matched by age, gender, and weight. By using(1)H-nuclear magnetic resonance (NMR) based metabolomics profiling of red blood cells (RBCs), we found that the metabolic signature of RBCs in T2D subjects differed significantly from non-diabetic controls. Affected metabolites included glutathione, 2,3-bisphophoglycerate, inosinic acid, lactate, 6-phosphogluconate, creatine and adenosine triphosphate (ATP) and several amino acids such as leucine, glycine, alanine, lysine, aspartate, phenylalanine and tyrosine. These results were validated by an independent cohort of T2D and control patients. An analysis of the pathways in which these metabolites were involved showed that energetic and redox metabolism in RBCs were altered in T2D, as well as metabolites transported by RBCs. Taken together, our results revealed that the metabolic profile of RBCs can discriminate healthy controls from T2D patients. Further research is needed to determine whether metabolic fingerprint in RBC could be useful to complement the information obtained from HbA1c and glycemic variability as well as its potential role in the diabetes management.
Filiaciones:
:
Ctr Invest Principe Felipe, NMR Facil, C Eduardo Primo YUfera 3, Valencia 46012, Spain
:
Ctr Invest Principe Felipe, NMR Facil, C Eduardo Primo YUfera 3, Valencia 46012, Spain
A. CIUDIN:
Autonomous Univ Barcelona, Vall dHebron Res Inst, Diabet & Metab Res Unit, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
CIBERDEM ISCIII, Av Monforte de Lemos 3-5, Madrid 28029, Spain
P. GUTIERREZ-CARCEDO:
Autonomous Univ Barcelona, Vall dHebron Res Inst, Diabet & Metab Res Unit, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
CIBERDEM ISCIII, Av Monforte de Lemos 3-5, Madrid 28029, Spain
Autonomous Univ Barcelona, Vall dHebron Res Inst, CIBBIM Nanomed, Med Mol Imaging Res Grp, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
R. MARES:
Autonomous Univ Barcelona, Vall dHebron Res Inst, CIBBIM Nanomed, Med Mol Imaging Res Grp, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
C. APARICIO-GOMEZ:
Autonomous Univ Barcelona, Vall dHebron Res Inst, CIBBIM Nanomed, Med Mol Imaging Res Grp, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
C. HERNANDEZ:
Autonomous Univ Barcelona, Vall dHebron Res Inst, Diabet & Metab Res Unit, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
CIBERDEM ISCIII, Av Monforte de Lemos 3-5, Madrid 28029, Spain
R. SIMO:
Autonomous Univ Barcelona, Vall dHebron Res Inst, Diabet & Metab Res Unit, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
CIBERDEM ISCIII, Av Monforte de Lemos 3-5, Madrid 28029, Spain
J. HERANCE:
Autonomous Univ Barcelona, Vall dHebron Res Inst, CIBBIM Nanomed, Med Mol Imaging Res Grp, Passeig Vall dHebron 119-129, Barcelona 08035, Spain
CIBER Bbn ISCIII, Av Monforte de Lemos 3-5, Madrid 28029, Spain
Gold, Green Published
|